|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{drugbox |
| | #REDIRECT [[Betaxolol#Pharmacology]] |
| | image=betaxolol.png
| |
| | IUPAC_name = 1-[4-[2-(cyclopropylmethoxy)<br>ethyl]phenoxy]-3-<br>(1-methylethylamino)propan-2-ol
| |
| | CAS_number = 63659-18-7
| |
| | ATC_prefix=C07
| |
| | ATC_suffix=AB05
| |
| | ATC_supplemental={{ATC|S01|ED02}}
| |
| | PubChem=2369
| |
| | DrugBank=APRD00245
| |
| | C=18 | H=29 | N=1 | O=3
| |
| |molecular_weight = 307.428 [[gram|g]]/[[Mole (unit)|mol]]
| |
| |bioavailability = 89%
| |
| |metabolism = [[Liver|Hepatic]]
| |
| |elimination_half-life = 14-22hours
| |
| |excretion = [[Kidney|Renal]] (20%)
| |
| |pregnancy_AU = C
| |
| |pregnancy_US = C
| |
| |pregnancy_category =
| |
| |legal_status = Rx-only
| |
| |routes_of_administration = oral, [[ocular]]
| |
| }}
| |
| __NOTOC__
| |
| {{CMG}}
| |
| | |
| {{Editor Join}}
| |
| | |
| | |
| | |
| | |
| ==Overview==
| |
| '''Betaxolol''' (trade names '''Betoptic''', '''Betoptic S''', '''Lokren''') is a selective [[beta blocker|beta<sub>1</sub> receptor blocker]] used in the treatment of [[hypertension]] and [[glaucoma]]. Being selective for beta<sub>1</sub> receptors, it typically has fewer systemic [[adverse drug reaction|side effect]]s than non-selective beta-blockers, for example, not causing [[bronchospasm]] (mediated by beta<sub>2</sub> receptors) as [[timolol]] may. Betaxolol also shows greater affininty for beta<sub>1</sub> receptors than [[metoprolol]]. In addition to its effect on the heart, betaxolol reduces the pressure within the eye ([[intraocular pressure]]). This effect is thought to be caused by reducing the production of the liquid (which is called the [[aqueous humor]]) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the [[optic nerve]] and loss of vision in patients with elevated intraocular pressure due to [[glaucoma]].
| |
| | |
| Betaxolol was approved by the U.S. [[Food and Drug Administration]] (FDA) for ocular use as a 0.5% solution ('''Betoptic''') in 1985 and as a 0.25% solution ('''Betoptic S''') in 1989.
| |
| | |
| ==See also==
| |
| [[Levobetaxolol]]
| |
| | |
| {{beta blockers}}
| |
| {{Antiglaucoma preparations and miotics}}
| |
| | |
| [[Category:Beta blockers]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |